Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC72985 structure
    GC72985Z-LEVD-FMK
    CAS: 1135688-25-3
    纯度: >98.00%

    Z-LEVD-FMK是一种细胞渗透性caspase-4抑制剂。

  • GC72991 structure
    GC72991(Rac)-Lisaftoclax
    CAS: 2651980-10-6
    纯度: >98.00%

    (Rac)-LisaftoclaxRac-APG-2575是一种Bcl-2抑制剂,可用于血液恶性肿瘤研究CN112898295A。

  • GC72994 structure
    GC72994RAPTA-C
    CAS: 372948-28-2
    纯度: >99.00%

    RAPTA-C (Ru(η - 6-p-cymene)Cl2(pta))是一种抗癌和抗血管生成剂。

  • GC73002 structure
    GC73002Ganglioside GD3 diammonium
    纯度: >98.00%

    Ganglioside GD3 diammonium是一种酸性鞘糖脂。

  • GC73016 structure
    GC73016AZD4877
    CAS: 758722-49-5
    纯度: >98.00%

    AZD4877是Ispinesib的另一种同分异构体,也是一种激酶纺锤体蛋白(Eg5)抑制剂,IC50为2 nM。

  • GC73025 structure
    GC73025Teprasiran sodium
    CAS: 2169310-72-7
    纯度: >90.00%

    Teprasiran sodium是一种小干扰RNA,可暂时抑制p53介导的细胞死亡,这是急性肾损伤(AKI)的基础。

  • GC73077 structure
    GC73077ARI-1
    纯度: >99.00%

    ARI-1是受体酪氨酸激酶样孤儿受体1 (ROR1)抑制剂的抑制剂。

  • GC73093 structure
    GC73093Custirsen sodium
    纯度: >98.00%

    Custirsen sodium抑制簇集蛋白的产生,簇集蛋白是一种抗凋亡蛋白,在化疗后上调,并赋予治疗耐药性。

  • GC73109 structure
    GC73109Danvatirsen sodium
    纯度: >97.00%

    Danvatirsen sodium是一种靶向STAT3的反义寡核苷酸,具有潜在的抗肿瘤活性。

  • GC73112 structure
    GC73112JPS014 TFA
    纯度: >98.00%

    JPS014 TFA是一种基于苯甲酰胺的Von Hippel-Lindau(VHL)E3连接酶蛋白水解靶向嵌合体(PROTAC)。

  • GC73118 structure
    GC73118EB1
    CAS: 42951-68-8
    纯度: >99.00%

    EB1是MNK激酶的抑制剂,ic50值分别为0.69 μM (MNK1)和9.4 μM (MNK2)。

  • GC73129 structure
    GC73129SIAIS164018 hydrochloride
    纯度: >99.00%

    SIAIS164018 hydrochloride是一种基于protac的ALK和EGFR降解剂,ALK和ALK G1202R的IC50值分别为2.5 nM和6.6 nM。

  • GC73133 structure
    GC73133Misetionamide
    CAS: 856785-75-6
    纯度: >99.00%

    Misetionamide是一种口服的类似恶硫嗪的化合物。

  • GC73136 structure
    GC73136VPC-70063
    CAS: 13571-44-3
    纯度: >99.00%

    VPC-70063是一种强效的Myc-Max抑制剂,抑制Myc-Max转录活性的IC50值为8.9μM。

  • GC73138 structure
    GC73138PBENZ-DBRMD
    CAS: 1454662-41-9
    纯度: >99.00%

    PBENZ-DBRMD是一种强效的碘三碱脱碘酶3型(DIO3)抑制剂。

  • GC73146 structure
    GC73146Sonrotoclax
    CAS: 2383086-06-2
    纯度: >99.00%

    Sonrotoclax是一种有效的口服活性Bcl2抑制剂。

  • GC73159 structure
    GC73159KTX-582
    CAS: 2573298-13-0
    纯度: >98.00%

    KTX-582是一种有效的IRAK4降解剂,IRAK4和Ikaros的DC50值分别为4nM和5nM。

  • GC73166 structure
    GC73166U7D-1
    纯度: >99.00%

    U7D-1是一流的有效和选择性USP7(泛素特异性蛋白酶7)PROTAC降解剂,在RS4;11细胞中的DC50为33 nM。

  • GC73168 structure
    GC73168p53 Activator 3
    CAS: 2636839-90-0
    纯度: >95.00%

    p53 Activator 3(化合物87A)是一种有效的p53激活剂,SC150值<0.05 mM。

  • GC73188 structure
    GC73188SFI003
    CAS: 2361332-90-1
    纯度: >99.00%

    SFI003是一种SRSF3抑制剂,通过SRSF3/DHCR24/ROS轴驱动CRC细胞凋亡,在体外和体内均表现出强大的抗肿瘤作用。

  • GC73199 structure
    GC73199M47
    CAS: 890808-56-7
    纯度: >99.00%

    M47是一种小分子,选择性地破坏隐色素1 (CRY1)的稳定性,并增加细胞核中CRY1的降解。

  • GC73210 structure
    GC73210MTR-106
    CAS: 1639357-93-9
    纯度: >99.00%

    MTR-106是一种强效的口服活性G-四链体稳定剂和RNA聚合酶I抑制剂。

  • GC73212 structure
    GC73212TH-6
    CAS: 3031349-25-1
    纯度: >95.00%

    TH-6是一种强效的HDAC抑制剂,HDAC1、HDAC2、HDAC3、HDAC6、HDAC8的IC50分别为0.115、0.135、0.242、0.138、2.120µM。

  • GC73220 structure
    GC73220LSD1-IN-24
    CAS: 4734-59-2
    纯度: >99.00%

    LSD1-IN-24(化合物3S)是一种选择性LSD1抑制剂,IC50 = 0.247 μM。